Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Inovio Pharmaceuticals Stock Broke Down in February

By George Budwell - Updated Apr 11, 2019 at 2:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A new debt offering weighed on the biotech's shares last month.

What happened

Shares of Inovio Pharmaceuticals ( INO -1.14% ), a clinical-stage immunotherapy company, fell by an unsightly 26% last month, according to data from S&P Global Market Intelligence. What event triggered this sell-off? 

Inovio's stock fell in response to a convertible debt offering halfway through the month. Investors apparently weren't pleased with either the terms of the debt offering or the fact that the initial purchasers decided not to buy the full allotment of additional notes.

Three red arrows smashing into the ground.

Image source: Getty Images.

So what

Inovio was attempting to raise $82.1 million in net proceeds with this convertible debt offering. However, the company walked away with only $75.8 million in total. While market conditions can dictate the interest from buyers in these types of offerings, Inovio's inability to sell the full allotment of additional notes seems to indicate that Wall Street isn't overly optimistic about the company's future. Biotech stocks, after all, are enjoying a strong resurgence this year and this capital raise wasn't particularly large for a company that sports a late-stage clinical asset.

Check out the latest earnings call transcript for Inovio Pharmaceuticals.

Now what

Capital raises -- even ones on unfavorable terms -- are part and parcel of the clinical-stage investing landscape. That's an inescapable drawback of investing in these types of equities. Thus, the market's overtly negative reaction to this offering is probably a bit overdone at this point. 

What really matters from an investing standpoint is that Inovio is now less than two years out from reporting top-line data for its lead vaccine candidate, VGX-3100. VGX-3100 is presently in a late-stage trial as a potential treatment for HPV-related cervical pre-cancer.

If this experimental vaccine scores a win in this ongoing trial, Inovio's share price should quickly return to form and then some. A failure, by contrast, will undoubtedly be greeted by another round of heavy selling. Given this binary outcome, capital raises shouldn't necessarily be a major point of concern for retail investors at this stage. The bigger deal is that Inovio has the funds necessary to complete its first-ever late-stage trial.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
$6.10 (-1.14%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/06/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.